Healthcare
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.(SHEZF)
Live Price
Offline$0.4696
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $13.56B
- Revenue Growth
- +3.8%
- EPS Growth
- -45.5%
- Dividend Yield
- 2.3%
Coverage: 251 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHEZF) is a Healthcare stock with a market cap of $13.56B and listed on OTC. The stock last traded around $0.47 and up 0.0% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +3.8%, EPS growth of -45.5%, a dividend yield of 2.3%. What stands out right now is revenue +3.8%, EPS -45.5%, free cash flow -20.1% with operating margin 12.3% and ROIC 3.8%. The dividend is present but secondary, with a yield around 2.3%. Valuation already assumes a fairly strong business story at P/E 41.9 and price/sales 2.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SHEZF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+3.8% vs +7.6% peer median
Operating Margin
Below sector median
+12.3% vs +19.4% peer median
P/E
Above sector median
41.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2025 was reported on Jun 30, 2025 with an EPS surprise of +826.8% and a revenue surprise of +14.1%.
The operating picture looks softer than before
Revenue is at +3.8% and EPS is at -45.5%, with operating margin around 12.3%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.3%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2025 Jun 30, 2025 | +826.8% | +0.0% | +0.0% | +0.0% |
2025 Apr 30, 2025 | +19.5% | +0.0% | +0.0% | +0.0% |
2024 Dec 31, 2024 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SHEZF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SHEZF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SHEZF and SPY.
Company Overview
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Other OTC
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.
- Leadership
- Li Li
- IPO Date
- Apr 13, 2021
- Employees
- 1.9k
- Street Address
- No. 21 Langshan Road
- Mailing
- Shenzhen, 518057
- Region
- Shenzhen, CN
- Reporting Currency
- USD
- Investor Line
- 86 755 2698 0200
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 41.9
- EV/EBITDA
- 14.4
- Price/Sales
- 2.5
- Price/Book
- 1.3
Growth
- Revenue
- +3.8%
- EPS
- -45.5%
- Free Cash Flow
- -20.1%
Profitability
- Gross Margin
- 33.5%
- Operating Margin
- 12.3%
- Net Margin
- 7.0%
- ROE
- 3.1%
- ROIC
- 3.8%
Balance Sheet
- Debt/Equity
- 0.23
- Current Ratio
- 2.15
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.